Brazil Cancer Chain to Vote on Freezing US Investor’s Rights Over Buyout
BRAZIL · MARKETS
Key Facts
- The country Brazil has about 213 million people and Latin America’s largest economy, similar in size to Italy’s. Its listed companies often write “poison pill” buyout rules into their bylaws to protect small shareholders.
- Why it matters Oncoclínicas runs one of Latin America’s largest private cancer-care networks. Its bylaws force any investor who passes 15% of the shares to offer to buy out everyone else.
- Why now On 25 August, Brazil’s securities regulator ruled 3-0 that a fund of US manager Centaurus Capital owes that buyout. No offer has been filed since.
- What happened On Thursday 24 September the board agreed, by majority, to call a shareholder meeting to suspend the fund’s rights. Three funds holding over 5% had asked on 15 September.
- Who is involved Asset manager Latache, now the largest shareholder, against Josephina III, the Centaurus fund. Goldman Sachs once held the stake through its own funds.
- What it means for you For holders of Brazilian stocks, it tests whether poison pills are enforced. The shares trade below R$2 (about US$0.39); estimates put the offer near R$16 (US$3.08).
- Still open The meeting date, which rights would be frozen, the offer price, and a pending arbitration case brought by the Centaurus side.
Brazil’s biggest private cancer-care group faces an Oncoclínicas shareholder vote on freezing the rights of one of its own investors. The target is a fund of Centaurus Capital, a US investment manager that regulators say owes the other shareholders a buyout offer.
On Thursday 24 September the board said it will call an extraordinary general meeting, a special vote outside the annual cycle. It acted on a request from three funds run by Latache, the Brazilian asset manager leading the minority camp.
What the board decided
The request reached the board on 15 September, signed by the funds Latache IV, Nova Almeida and Latache MHF I. Together they hold more than 5% of the company’s capital. The board approved the call by a majority, not unanimously.
In its filing it said it made no judgement on the merits, because the decision belongs to shareholders alone. The formal notice with a date had not been published by Sunday 27 September.
The company said only that the meeting would be called in the coming days. Brazilian law requires at least 21 days’ notice for a listed company’s general meeting.
That puts the vote at least three weeks after the notice appears.
What the Oncoclínicas shareholder vote would do
The proposal is to suspend every right of Josephina III that can legally be suspended. The freeze would start on the day of the vote and last until the buyout is fully completed.
Josephina III would not be allowed to vote on its own suspension. The request does not list the affected rights one by one.
Two rules support the request. Article 120 of Brazil’s corporate law lets shareholders suspend the rights of any holder who breaks a legal or bylaw duty.
The company’s bylaws go further. Article 39, paragraph 5, orders the board to call such a meeting when a 15% holder fails to make the offer.
Latache used article 123 of the same law, which lets holders of at least 5% demand a meeting. If the board fails to act within eight days, they may call it themselves.
Latache also warned it would hold directors liable if they ignored the request, the business outlet Capital Aberto reported.
The buyout the regulator ordered
The dispute goes back to 4 November 2024. A reorganization of funds long managed by Goldman Sachs left Josephina III holding 16.05% of Oncoclínicas directly, above the 15% trigger.
In March 2025 a private share purchase lifted the fund’s stake to 31.83%. That figure comes from regulatory documents cited by Times Brasil, the local CNBC affiliate.
On 25 August 2026 the CVM, Brazil’s version of the US Securities and Exchange Commission, ruled 3-0 that the offer is owed. The ruling is covered in Brazil’s CVM Orders Oncoclínicas Tender Offer for Minorities.
The vote overturned the CVM’s own technical staff, which had found in June that no offer was required. The board gave that staff up to 60 days to take the steps needed to enforce the obligation.
The regulator also found that the bylaws’ original deadline had already passed with no offer registered. That missed deadline is the core of the Latache request.
How much money is at stake
The price has not been set. It must follow a formula in article 39 of the bylaws, adjusted by Brazil’s benchmark Selic interest rate from 4 November 2024.
Press estimates put the price at up to R$16 per share (about US$3.08), based on January 2024 trading. The stock now trades below R$2 (about US$0.39).
Capital Aberto puts the total offer above R$6 billion (about US$1.16 billion). The outlet Money Times cites market estimates near R$11.7 billion (about US$2.25 billion).
Figures here use a rate of 5.19 reais to the US dollar, the open.er-api.com rate for 27 September 2026.
How the Centaurus side sees it
Centaurus and Goldman Sachs argue that the manager already had economic exposure above 15% before the company listed its shares in 2021. In their view the 2024 reorganization only made an existing stake direct.
That reading would fit an exception written into the bylaws. The CVM board rejected it, finding that indirect exposure was not the same as owning shares.
This is not the first attempt. Latache asked for a similar meeting in May 2025, and the board turned it down on 13 August 2025, Times Brasil reported.
At the time the Josephina funds called the move a manoeuvre. They argued that only the CVM or an arbitration panel could decide whether the bylaws had been breached.
The Centaurus side has since opened arbitration against the three Latache funds. The case sits at the market arbitration chamber of B3, the São Paulo stock exchange.
A company already under strain
The fight lands on a business in financial trouble. In July Oncoclínicas began a court-backed restructuring of about R$5.1 billion (about US$983 million) of debt.
Its cash crisis included losing about R$430 million (about US$82.9 million) at Banco Master, a bank liquidated in November 2025. Ownership has shifted too.
Latache holds 14.59% and is now the largest shareholder, while Josephina III cut its stake to 9.91% in July, Capital Aberto reports. The CVM found that dropping below 15% later does not cancel the obligation.
Separately, the group sold a Spanish research stake on 22 September, covered in Brazil’s Oncoclínicas Sells Spanish Research Stake for Symbolic US$1.14.
What comes next
The next step is the formal notice, which must name a date, time and agenda. Josephina III will be barred from the Oncoclínicas shareholder vote on its own rights.
If approved, the suspension would last until the offer is completed. The Centaurus side may challenge it through arbitration or the courts; it has not said publicly how it will respond.
The meeting does not set the offer price or force payment by itself. It adds pressure, while the CVM staff handle enforcement of the ruling already made.
The vote concerns shareholder rights only. It does not change how the group’s cancer clinics are run.
Frequently Asked Questions
What is Oncoclínicas?
A Brazilian private cancer-care group running more than 140 units in 49 cities, according to the company. Its shares trade on the São Paulo stock exchange under the ticker ONCO3.
Who is Josephina III?
An investment fund through which the US manager Centaurus Capital holds its Oncoclínicas shares. It was once part of a group of funds managed by Goldman Sachs.
Why do the Latache funds want its rights suspended?
Brazil’s regulator ruled on 25 August 2026 that Josephina III and Centaurus owe the other shareholders a buyout offer under the bylaws. No offer has been made, and the bylaws allow a meeting to freeze the rights of an investor who fails that duty.
When will shareholders vote?
No date had been published by 27 September 2026. Brazilian law requires at least 21 days’ notice, so the vote comes at least three weeks after the notice.
Sources: Oncoclínicas material fact of 24 September 2026, as reported by Estadão/Broadcast, Money Times, Times Brasil (CNBC), Capital Aberto, ADVFN and Atlas Público; Brazilian Corporations Law (Lei 6.404/1976), articles 120, 123 and 124, via planalto.gov.br; CVM board decision of 25 August 2026; Bloomberg Línea; exchange rate open.er-api.com, 27 September 2026.
Company profiles: PDG Realty S.A.
Company profiles: Dimed S.A.
Company profiles: Pettenati S.A.
Company profiles: Randon S.A.
Company profiles: Guararapes Confecções S.A.
This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error
Brazil runoff, Sunday, October 25: Brazil runoff start time and results schedule. Latest: Brazil runoff polls, Flávio 51%, Lula 49%.